Cite
HARVARD Citation
Berdeja, J. et al. (n.d.). Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma. European journal of cancer. pp. S5-. [Online].